Newron Pharmaceuticals has secured 44 million euros ($46.1 million) in upfront cash from an Eisai subsidiary for select Asia ...

Italy-based CNS specialist Newron Pharmaceuticals has entered into a license agreement with EA Pharma, part of Japan’s Eisai, ...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word (s): Agreement Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian ...

Newron and EA Pharma sign licence for evenamide in Japan & Asia. Newron to receive up to €117 million from upfront payments, milestones and royalties.

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States.

Return on common equity for Newron Pharmaceuticals is not meaningful. Looking back at the last 5 years, Newron Pharmaceuticals's return on common equity peaked in December 2019 at -44.1%.

Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year.

Newron Pharmaceuticals has clearance to press ahead with phase 3 development of its schizophrenia drug Evenamide after the FDA agreed a plan to address potential safety issues emerging from ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...